Raffaella Molteni

Raffaella Molteni

Auto-generated profile, based on publicly available information

Raffaella Molteni

Vita-Salute San Raffaele University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RMRaffaella Molteni
Raffaella Molteni
MFMartina Fiumara
Martina Fiumara
CCCorrado Campochiaro
Corrado Campochiaro
RARoberta Alfieri
Roberta Alfieri
GPGuido Pacini
Guido Pacini
SFSamuele Ferrari
Samuele Ferrari
Clonal dominance characterizes hematopoiesis during aging and increases susceptibility to blood cancers and common nonmalignant disorders. VEXAS syndrome is a recently discovered, adult-onset, autoinflammatory disease burdened by a high mortality rate and caused by dominant hematopoietic clones bearing somatic mutations in the UBA1 gene. However, pathogenic mechanisms driving clonal dominance are unknown. Moreover, the lack of disease models hampers the development of disease-modifying therapies. In the present study, we performed immunophenotype characterization of hematopoiesis and single-cell transcriptomics in a cohort of nine male patients with VEXAS syndrome, revealing pervasive inflammation across all lineages. Hematopoietic stem and progenitor cells (HSPCs) in patients are skewed toward myelopoiesis and acquire senescence-like programs. Humanized models of VEXAS syndrome, generated by inserting the causative mutation in healthy HSPCs through base editing, recapitulated proteostatic defects, cytological alterations and senescence signatures of patients’ cells, as well as hematological and inflammatory disease hallmarks. Competitive transplantations of human UBA1-mutant and wild-type HSPCs showed that, although mutant cells are more resilient to the inflammatory milieu, probably through the acquisition of the senescence-like state, wild-type ones are progressively exhausted and overwhelmed by VEXAS clones, overall impairing functional hematopoiesis and leading to bone marrow failure. Our study unveils the mechanism of clonal dominance and provides models for preclinical studies and preliminary insights that could inform therapeutic strategies.

5 November 2025 in Current Opinion in Rheumatology
Verified
Journal Article
Open access
MFMartina Fiumara
Martina Fiumara
CCCorrado Campochiaro
Corrado Campochiaro
RMRaffaella Molteni
Raffaella Molteni
Purpose of review: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a newly discovered, adult-onset, hemato-inflammatory disease driven by clonal dominance of pro-inflammatory hematopoietic cells bearing a somatic mutation in the UBA1 gene. This review aims to integrate and discuss the most recent insights into the evolving understanding of VEXAS pathogenesis and clinical management. Recent findings: An interplay between inflammation and clonal dominance of UBA1 mutant hematopoietic clones underlies the pathogenesis of VEXAS syndrome. Mutant cells both generate and sustain a toxic inflammatory milieu that impairs wild-type hematopoiesis. Despite exhibiting dysfunctional differentiation, VEXAS cells activate pro-survival pathways that support their persistence and progressive dominance. Recent international guidelines offer evidence-based recommendations to optimize therapy and manage both inflammatory and hematologic features of the disease. Summary: This review dissects the key molecular mechanisms driving inflammation and clonal survival in UBA1 mutant cells, and outlines current therapeutic strategies proposed to counteract VEXAS progression and improve patient outcomes. The recent findings presented here, along with the deeper understanding that will be built upon them, not only advance the knowledge of the disease pathobiology, but also pave the way for more precise, mechanism-driven treatment approaches aimed at intercepting disease progression and improving long-term outcomes.